APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S. 504, The Fair and Immediate Release of Generics Act, provisions relating to market blockages caused by parked 180 day exclusivity periods; S. 214, The Preserve Access to Affordable Pharmaceuticals Act, provisions relating to the legality of "reverse payment" patent settlements;Federal Trade Commission v. Actavis Supreme Court Case No. 12-416 as this case pertains to S. 504, S. 214, and to federal policy on "reverse payment" settlements; Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; H.R. 1919, the Safeguarding America's Pharmaceutical Act of 2013, S. 959, the Pharmaceutical Compounding Quality and Accountability Act, Title II, Drug Supply Chain Security, HR 3204, the Drug Quality and Security Act, Title II, Drug Supply Chain Security, provisions relating to the establishment of a federal track and trace system for pharmaceuticals; Implementation of Public Law 112-144 The Food and Drug Administration Safety and Innovation Act, federal policy relating to provisions in Title 3 regarding generic drug user fees; Federal policy relating to International Nonproprietary Names for biosimilars
Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Shermfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.